Peptide Initiative

Peptides · Peptide comparison

Kisspeptin-10 vs PT-141 (Bremelanotide)

A powerful reproductive hormone regulator that acts like the master switch for your body's fertility system—triggering the release of hormones that control everything from ovulation to testosterone production.

The first FDA-approved peptide that works through your brain to reignite sexual desire—think of it as flipping the 'on' switch for arousal rather than just boosting blood flow like traditional ED meds.

  • Sexual Health
  • Sexual Health

At a glance

Quick comparison

Dose rangeKisspeptin-10100–100 mcgPT-141 (Bremelanotide)1.75–1.75 mg
FrequencyKisspeptin-10Once dailyPT-141 (Bremelanotide)As needed
AdministrationKisspeptin-10Subcutaneous injectionPT-141 (Bremelanotide)Subcutaneous injection
Cycle lengthKisspeptin-104-6 weeksPT-141 (Bremelanotide)Ongoing/indefinite
Onset speedKisspeptin-10Rapid (hours to days)PT-141 (Bremelanotide)Rapid (hours to days)
Evidence levelKisspeptin-10Moderate human trials (Phase 1-2)PT-141 (Bremelanotide)Strong human trials (Phase 3 or FDA approved)

Efficacy

Benefit ratings

Hormone Activation

Kisspeptin-1094%
PT-141 (Bremelanotide)No recorded rating

Sexual Health

Kisspeptin-1089%
PT-141 (Bremelanotide)No recorded rating

Fertility Support

Kisspeptin-1092%
PT-141 (Bremelanotide)No recorded rating

Sexual Desire

Kisspeptin-10No recorded rating
PT-141 (Bremelanotide)92%

On-Demand Use

Kisspeptin-10No recorded rating
PT-141 (Bremelanotide)95%

Clinical Evidence

Kisspeptin-10No recorded rating
PT-141 (Bremelanotide)98%

Technical data

Compound specifications

Kisspeptin-10

Molecular formula
C63H83N17O14
Molecular weight
1302.45 g/mol
Half-life
~4 minutes (IV); slightly longer subcutaneously
Bioavailability
High when injected; lower intranasal but still effective
CAS number
374675-21-5

PT-141 (Bremelanotide)

Molecular formula
C50H68N14O10
Molecular weight
1025.2 g/mol
Half-life
2.7 hours
Bioavailability
~100% (subcutaneous injection)
CAS number
189691-06-3

Protocols

Dosing compared

Kisspeptin-10

Subcutaneous

  • 50 mcg per injectionOnce daily · 1-2 weeksConservative subcutaneous entry dose used in research practice; kisspeptin-10 has a very short half-life (~4 min IV) so effects are pulse-like [1].
  • 100 mcg per injectionOnce daily · 4-6 weeksCommon research/practice subcutaneous dose; roughly approximates the ~1 mcg/kg level shown to maximally stimulate LH in men [6].
  • 100-200 mcg per injectionOnce or twice daily · 4-6 weeksUpper end of the practice range; higher kisspeptin-10 doses can blunt the LH response (a ceiling/desensitization effect was seen above ~1 mcg/kg) so escalating beyond this is not advised [6].

Intravenous

  • 1 mcg/kg bolusSingle bolus (research setting) · Single administrationPeer-reviewed human dose: an IV bolus of 1 mcg/kg produced the greatest LH stimulation in healthy men (rising from ~4 to ~12 IU/L at 30 min); 3 mcg/kg gave a smaller response [6]. Used in clinical research, not for routine self-administration.

PT-141 (Bremelanotide)

Subcutaneous

  • 1 mgAs needed, ~45 min before sexual activity; no more than once per 24 h · Trial period (assess response/tolerability)Not a labelled dose: VYLEESI comes only as a 1.75 mg single-dose autoinjector [7]. A 1 mg starting dose is community practice with compounded powder, used to gauge nausea. Inject into abdomen or thigh.
  • 1.75 mgAs needed, ~45 min before sexual activity; max once per 24 h and 8 doses per 28 days · Ongoing as neededFDA-approved Vyleesi dose for hypoactive sexual desire disorder in premenopausal women; efficacy shown in the RECONNECT phase 3 trials [1][6].

Applications

Best suited for

Kisspeptin-10

Fertility and IVF Support
Kisspeptin is showing remarkable promise as a safer alternative to traditional IVF triggers. Unlike hCG, it dramatically reduces the risk of ovarian hyperstimulation syndrome (OHSS)—a potentially dangerous IVF complication. Studies show kisspeptin can mature eggs effectively while keeping ovarian volume 3x smaller than with hCG [3][13].
Natural Testosterone Optimization in Men
Rather than replacing your testosterone from outside (which shuts down natural production), kisspeptin tells your brain to make more. It stimulates LH release, which signals your testes to produce testosterone naturally. [6][7] This approach maintains fertility and testicular function—unlike exogenous testosterone [22].
Low Sexual Desire (Hypoactive Sexual Desire Disorder)
Clinical trials have shown kisspeptin enhances brain activity in regions involved in sexual arousal and attraction. In men with HSDD, it increased penile response by up to 56% and improved happiness about sex. In women, it modulated brain areas involved in sexual and attraction processing [1][2].
Hypothalamic Amenorrhea Recovery
For women who've lost their periods due to stress, low body weight, or over-exercise, kisspeptin can help restart the reproductive system. It acts on the hypothalamus to reinitiate GnRH pulsing—the first step in bringing periods back naturally [5][12].

PT-141 (Bremelanotide)

Women with Low Sexual Desire (HSDD)
PT-141 is FDA-approved specifically for premenopausal women with acquired, generalized hypoactive sexual desire disorder—when you used to have normal desire but it's faded, and it's causing real distress in your life. It's the only approved treatment that works through brain pathways rather than hormones.
Men Who Don't Respond to Viagra-Type Medications
While not FDA-approved for men, clinical research shows PT-141 may help men with erectile dysfunction who don't respond to PDE5 inhibitors like Viagra or Cialis. Because it works through the brain rather than blood vessels, it offers a completely different approach.
Those Wanting On-Demand Treatment
Unlike daily medications like flibanserin (Addyi), PT-141 is used only when you want it—take it 45 minutes before intimacy. This gives you control over timing without committing to daily pills.
People Seeking to Address the 'Wanting' Part of Intimacy
Many sexual health treatments focus on the physical mechanics (blood flow, lubrication). PT-141 is unique because it targets desire itself—the psychological 'wanting' that initiates intimacy. It works on your brain's arousal circuits.

Safety profile

Side effects

Kisspeptin-10

Common

  • Flushing or warmth
  • Injection site reactions
  • Mild headache

Uncommon

  • Temporary heart rate increase
  • Dizziness

Serious

  • Allergic reaction

PT-141 (Bremelanotide)

Common

  • Nausea
  • Facial flushing
  • Headache
  • Injection site reactions

Uncommon

  • Skin darkening (hyperpigmentation)

Serious

  • Blood pressure increase

Research status

Safety & evidence

Kisspeptin-10

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Kisspeptin has demonstrated an excellent safety profile across multiple clinical trials at Imperial College London and other research centers. Studies involving healthy volunteers and patients with reproductive disorders have shown no serious adverse events. [5][13] The most common effects—flushing and feeling warm—are related to its mechanism of action and resolve quickly. [15][20] Importantly, kisspeptin doesn't cause anxiety or negative psychological effects, which was confirmed in a study of 95 participants [4].

Contraindications

  • Pregnancy or planning to become pregnant
  • Hormone-sensitive cancers (breast, prostate, ovarian)
  • Known allergy to peptide components
  • Children and adolescents (unless under specialist care for delayed puberty)

PT-141 (Bremelanotide)

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
PT-141 (bremelanotide) was approved by the FDA in 2019 as VYLEESI after two 24-week phase 3 trials in 1,247 premenopausal women. [1][7] Nausea was the most common reaction (40% vs 1% on placebo): it affected 21% after the first dose and about 3% after later doses, and 8% stopped treatment because of it. [7] Each dose raises blood pressure by up to 6/3 mmHg, peaking 2–4 hours after the dose, and lowers heart rate by up to 5 beats per minute, usually back to baseline within 12 hours. It is contraindicated in uncontrolled hypertension or known cardiovascular disease. [7] Focal hyperpigmentation occurred in 1% at up to 8 doses a month. [7] The 52-week open-label extension found no new safety signals. [2]

Contraindications

  • Uncontrolled high blood pressure [7]
  • Cardiovascular disease [7]
  • History of heart attack or stroke [7]

Decision guide

Which is right for you?

Kisspeptin-10

Choose Kisspeptin-10 if…

  • Fertility support and optimization
  • Natural testosterone enhancement
  • IVF treatment (oocyte maturation)
  • Sexual health and libido improvement

PT-141 (Bremelanotide)

Choose PT-141 (Bremelanotide) if…

  • Restoring sexual desire
  • Treating hypoactive sexual desire disorder (HSDD)
  • Enhancing arousal response
  • Supporting intimacy when desire is low